NasdaqCM - Nasdaq Real Time Price • USD
Mereo BioPharma Group plc (MREO)
At close: May 15 at 4:00 PM EDT
After hours: May 15 at 7:56 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2019) | Next Qtr. (Mar 2020) | Current Year (2019) | Next Year (2020) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2019) | Next Qtr. (Mar 2020) | Current Year (2019) | Next Year (2020) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | 1 | 1 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | 4.4M |
| High Estimate | -- | -- | -- | 4.4M |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | ||||
|---|---|---|---|---|
| EPS Est. | -- | -- | -- | -- |
| EPS Actual | -- | -- | -- | -- |
| Difference | -- | -- | -- | -- |
| Surprise % | -- | -- | -- | -- |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Dec 2019) | Next Qtr. (Mar 2020) | Current Year (2019) | Next Year (2020) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | -0.26 | 0 | -0.47 | -52 |
| 30 Days Ago | -0.26 | 0 | -0.47 | -52 |
| 60 Days Ago | -0.26 | 0 | -0.47 | -52 |
| 90 Days Ago | -0.26 | 0 | -0.47 | -52 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Dec 2019) | Next Qtr. (Mar 2020) | Current Year (2019) | Next Year (2020) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | -- |
| Up Last 30 Days | -- | -- | 1 | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | MREO | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 8.30% |
| Next Qtr. | -- | -- | -- | 12.40% |
| Current Year | -- | -- | -- | 5.60% |
| Next Year | -- | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 11.13% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Needham: Buy to Buy | 4/10/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 3/28/2024 |
| Maintains | Needham: Buy to Buy | 3/28/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 3/22/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 9/8/2023 |
| Reiterates | Needham: Buy to Buy | 9/8/2023 |
Related Tickers
PDSB PDS Biotechnology Corporation
3.5000
-0.99%
XFOR X4 Pharmaceuticals, Inc.
0.9762
-0.93%
DAWN Day One Biopharmaceuticals, Inc.
16.42
-1.20%
MDNAF Medicenna Therapeutics Corp.
1.8150
-4.47%
EFTR eFFECTOR Therapeutics, Inc.
1.9800
-1.00%
CLRB Cellectar Biosciences, Inc.
3.3600
+5.66%
CRVS Corvus Pharmaceuticals, Inc.
2.2200
-1.77%
LPTX Leap Therapeutics, Inc.
2.8000
+1.82%
RARE Ultragenyx Pharmaceutical Inc.
41.12
+0.37%
CYTK Cytokinetics, Incorporated
60.50
+1.92%